Methods of preparing kinase inhibiting pharmaceutical compounds having the formula (I): ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sub.1 through R.sub.6 and Z are as described in the specification. The methods according to the invention utilize an amination process, in which a pyrrole is reacted with a haloamine, preferably chloramine. This step is followed by cyclization to form the pyrrolotriazine core.